Atorvastatin/CoenzymeQ10 in Congestive Heart Failure
Recruitment status was Recruiting
The aim of this study is to compare the effect of addition of combination of Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus addition of Atorvastatin alone on CHF outcomes.
Congestive Heart Failure
Drug: Coenzyme Q10
Drug: placebo for coenzyme Q10
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
- Change in cardiac Ejection Fraction (EF) [ Time Frame: Baseline for the first time and after 4 months for the second time ] [ Designated as safety issue: No ]For the determination of change in EF,cardiac EF was determined two times . Baseline :at the beginning of study(before intervention) and the second time after 4 months(after intervention).
- Change in New York Heart Association Function Class [ Time Frame: Baseline for the first time and after 4 months for the second time ] [ Designated as safety issue: No ]For the determination of change in New York Heart Association Function Class.it was determined two times .Baseline:at the beginning of study(before intervention)and the second time after 4 months(after intervention).
|Study Start Date:||June 2013|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Experimental: Coenzyme Q10 & Atorvastatin
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
|Drug: Atorvastatin Drug: Coenzyme Q10|
Active Comparator: Atorvastatin & placebo
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
|Drug: Atorvastatin Drug: placebo for coenzyme Q10|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01925937
|Contact: Amin Nemati, MDemail@example.com|
|Iran, Islamic Republic of|
|Vice Chancellery for Research of Isfahan University of Medical Sciences, Isfahan, Iran||Recruiting|
|Isfahan, Iran, Islamic Republic of, 8174673461|
|Contact: Amin Nemati, MD 00989131009918 firstname.lastname@example.org|
|Principal Investigator: Javad Shahabi, MD|
|Study Director:||Masoud Pourmoghaddas, cardiologist||Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.|